Myeloproliferative neoplasms (MPN) are a closely related group of progressive hematological disorders that are indiscriminate to age and gender. There is currently no known cure and the prognosis is usually shortened life expectancy, but if diagnosed early, symptom management can prolong and provide viable quality of life. The IMPACTLive MPN educational series was designed to advance MPN awareness in the healthcare community so that patients can be diagnosed, referred, and treated sooner, resulting in overall improved patient outcomes.
A multidisciplinary approach is required for optimal management of patients with MPNs; therefore, it is critical that healthcare professionals from various disciplines understand the rapidly emerging clinical data to improve the outcomes of their patients.
The learning modules in this program cover a range of topics, from the more general aspects of MPN, to specific clinical situations. Whenever practical, a case-based approach is used so that health professionals can follow the diagnostic pathway, using the appropriate tools to monitor disease progression and begin treatment cycles earlier, resulting in overall improved clinical outcomes through improved symptom control.
Myeloproliferative Neoplasms: Contemporary Management and Unmet Needs
The past decade has seen major advances in our understanding of the biology and clinical management of the BCR-ABL-negative myeloproliferative neoplasms (MPNs): polycythemia vera, essential thrombocythemia, and myelofibrosis. These MPNs are characterized by their burdensome symptom profiles, life-threatening complications, and risk of progression to acute myeloid leukemia. This program provides an up-to-date review of contemporary principles and standards for management of MPNs. It is specially designed for hematologists and other point-of-care professionals who diagnose and treat hematologic diseases, including those who may encounter MPNs infrequently. Following a primer on each MPN, interactive case-based segments enable participants to consider differential diagnosis, disease status, and treatment for individual patients. Current and emerging roles for standard and JAK2 inhibitor therapy are included, as well as discussions of key challenges and ongoing research. This educational program is an ideal opportunity to gain the latest knowledge on MPNs and new strategies to optimize patient management and outcomes.
CE Statement/Credit Designation
Physician Continuing Medical Education
Your institution will select a faculty presenter and topic, and provide the in-hospital venue. Mentor Meetings and Events with work with an on-site representative to assist with logistical planning as needed.
Held at a restaurant, this program will include the selection of a speaker and topic for a one hour lecture with question-and- answer session (1.0 credit hour). Site selection will comply with ACCME and PhRMA guidelines, and will include a modest meal selection. These are generally private programs for an individual practice group.
Lunch (or breakfast) Meeting
Held at your practice, this program includes a one hour lecture with question-and-answer session (1.0 credit hour). This format will include a modest meal selection, compliant with ACCME and PhRMA guidelines. This program may be for a single practice, or multiple practice groups.
This format may include multiple speakers and lecture topics. Please speak to a representative at Mentor Meetings and Events to plan this event.
Compliance with Sunshine Act
The National Physician Payment Transparency Program (Sunshine Act) is a section of the Patient Protection and Affordable Care Act of 2010 that requires pharmaceutical and medical device companies to report to the Federal government certain payments (e.g. meals and other meeting expenses) they make to physicians and teaching hospitals. IMPACTLive MPN programs fully comply with the Sunshine Act and, as a result, payments may be reportable based upon these requirements. For detailed information, please visit www.cms.gov.
Ruben Mesa, MD, FACP
Chair, Division of Hematology & Medical Oncology
Mayo Clinic Cancer Center